ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 0588 • ACR Convergence 2024

    Sex-Related Differences in Baseline Patient and Disease Characteristics: Post Hoc Analyses of Three Phase 3, Randomized, Double-blind, Placebo-Controlled Studies in Patients with Active Psoriatic Arthritis

    Laura Coates1, Carlo Selmi2, Philip Mease3, Alexis Ogdie4, Francois Nantel5, Frederic Lavie6, Mohamed Sharaf7, Oyediran Adelakun8, Emmanouil Rampakakis9, Laura Pina Vegas10 and Lihi Eder11, 1University of Oxford, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford, United Kingdom, 2Department of Biomedical Sciences, Humanitas University, Rozzano, Italy, 3Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA, 4Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 5Nantel MedSci Consult, Montreal, QC, Canada, 6Janssen Cilag Global Medical Affairs, Immunology Global Medical Affairs, Issy les Moulineaux, France, 7Johnson & Johnson, Middle East FZ LLC, Dubai, UAE, Dubai, United Arab Emirates, 8Janssen Research & Development, LLC, Titusville, NJ, 9McGill University, Department of Pediatrics / Scientific Affairs, JSS Medical Research Inc., Montreal, QC, Canada, 10Leiden University Medical Center, Leiden, Netherlands, 11University of Toronto, Women’s College Hospital and Department of Medicine, Toronto, ON, Canada

    Background/Purpose: Although PsA occurs in males and females at similar rates, clinical manifestations and outcomes differ between sexes. Findings from real-world evidence (RWE) studies have…
  • Abstract Number: 0580 • ACR Convergence 2024

    Cellular Immune Activation Signatures at Baseline Predict Response to TNF Inhibitors in Axial Spondyloarthritis

    Ayantika Talukdar1, Neke Ibeh2, Rohan Machhar2, Mansi Aparnathi3, Sareh Keshavarazi4, Archita Srinath5, Akihiro Nakamura6, Robert Inman7, Proton Rahman8, Igor Jurisica9 and Nigil Haroon10, 1Krembil Research Institute, UHN, Toronto, ON, Canada, 2UHN, Toronto, Canada, 3University Health Network, Toronto, Canada, 4UHN, Toronto, ON, Canada, 5University of Toronto, Toronto, ON, Canada, 6Queen's Univesity, Kingston, ON, Canada, 7University Health Network, Toronto, ON, Canada, 8Memorial University of Newfoundland, Faculty of Medicine, Division of Rheumatology, St. John's, Canada, 9Departments of Medical Biophysics and Computer Science and Faculty of Dentistry, University of Toronto and Institute of Neuroimmunology, Slovak Academy of Sciences, Bratislava, Slovakia, Toronto, ON, Canada, 10Department of Medicine/Rheumatology, University Health Network, Schroeder Arthritis Institute, University of Toronto, Toronto, ON, Canada

    Background/Purpose: Tumor necrosis factor inhibitors (TNFi) substantially improve symptoms in Ankylosing Spondylitis (AS), although 40% patients are unresponsive. Identifying biomarkers predictive of TNFi treatment response…
  • Abstract Number: 0637 • ACR Convergence 2024

    Active Implementation of Low Disease Activity State as Treatment Endpoint in a Large Cohort of Adolescents and Young Adults with Childhood Onset Systemic Lupus Erythematosus

    Ruby Gotch1, Yumna Ahmed1, Robert Wilson1, Ellie Hawkins1 and Coziana Ciurtin2, 1University College London Hospital NHS Trust, London, United Kingdom, 2University College London, London, United Kingdom

    Background/Purpose: Treat-to-target (T2T) strategies are focused on proactive and tailored management of disease activity to minimise damage risk and improve long-term outcomes in SLE across…
  • Abstract Number: 0650 • ACR Convergence 2024

    Tubulointerstitial Inflammation Predicts Tubular Atrophy, Fibrosis, and Renal Function Loss in Lupus Nephritis

    Yevgeniya Gartshteyn1, Laura Geraldino2, Shuwei Wang3, Vivette D'Agati1 and Robert Winchester1, 1Columbia University Irving School of Medicine, New York, NY, 2Division of Rheumatology, Department of Medicine, Columbia University, New York, NY, 3Rutgers New Jersey Medical School, Newark, NJ

    Background/Purpose:     Current classification criteria of lupus nephritis (LN) emphasize glomerular pathology, however tubular atrophy and interstitial fibrosis (TAIF) are better predictors of poor…
  • Abstract Number: 0681 • ACR Convergence 2024

    Influence of Occupational Exposure to Pollutants on Clinical and Serological Phenotypes in Systemic Sclerosis

    Martina Sanahuja i Sanz1, Irene Carrión-Barberà2, Laura Tío3, Laura Triginer3, María Lee3, Alfredo Guillén-del Castillo4, Anna Ribes3, Lidia Valencia Muntalà5, Jordi Monfort2, Tarek Carlos Salman Monte:6, Javier Narvaez-García7, Carmen PIlar Simeón-Aznar4 and Anna Pros2, 1Universitat Pompeu Fabra, Barcelona, Spain, 2Hospital del Mar, Barcelona, Spain, 3Hospital del Mar Research Institute, Barcelona, Spain, 4Hospital Vall d'Hebron, Barcelona, Spain, 5Hospital de Bellvitge, Barcelona, Spain, 6Hospital del Mar/Parc de Salut Mar-IMIM, Barcelona, Spain, 7Hospital Universitario de Bellvitge, Barcelona, Spain

    Background/Purpose: Environmental factors have been proposed as a trigger for systemic sclerosis (SSc) in genetically predisposed individuals. This study aimed to investigate the association between…
  • Abstract Number: 0668 • ACR Convergence 2024

    There Are No Shortcuts: Electronic Health Record-Generated Tool Does Not Reflect Medication Adherence in Patients with SLEin Bronx, NY

    Kiera Brennan1, Kai Sun2, Anitha Ramu1, Juliann Allen1, Justina Shafik1 and Noa Schwartz3, 1Albert Einstein College of Medicine, Bronx, NY, 2Duke University, Durham, NC, 3Albert Einstein College of Medicine, New York, NY

    Background/Purpose: Nonadherence to hydroxychloroquine (HCQ) is associated with poor outcomes in SLE.1 Electronic Health Record (EHR) platforms collect data on patient medication access through dispensing…
  • Abstract Number: 0611 • ACR Convergence 2024

    Subclinical Atherosclerosis Is Associated with Future Cardiovascular Events in Systemic Lupus Erythematosus Patients at Apparent Low Risk for Cardiovascular Disease: A Longitudinal Prospective Study

    Arthur Mageau1, Marie-Paule Chauveheid2, Chrystelle Francois2, Thomas Papo1 and Karim Sacré1, 1Université Paris Cité, Paris, France, 2Assistance Publique Hôpitaux de Paris, Paris, France

    Background/Purpose: Cardiovascular events (CVE) are the leading cause of mortality for patients living with systemic lupus erythematosus (SLE). Besides the traditional cardiovascular risk factors, the…
  • Abstract Number: 0643 • ACR Convergence 2024

    Using FDG PET Brain Scans and Deep Learning Analyses to Identify a Specific Network Correlated with Cognitive Impairment in SLE

    Nha Nguyen1, An Vo1, Chris Tang1, Erik Anderson2, Cynthia Aranow2, Betty Diamond3, David Eidelberg1 and Meggan Mackay4, 1Feinstein Institutes, Manhasset, NY, 2Feinstein Institutes for Medical Research, New York, NY, 3The Feinstein Institutes for Medical Research, Manhasset, NY, 4Feinstein Institutes for Medical Research, Manhasset, NY

    Background/Purpose: Cognitive impairment (CI) is a debilitating, untreatable problem for up to 80% of individuals with SLE and human and mouse data suggest multiple SLE-related…
  • Abstract Number: 0565 • ACR Convergence 2024

    Low Vitamin D Serum Level Is a Risk Factor for Ankylosis in Axial Spondyloarthritis: Evidence from a Nested-Case-Control Study

    Anthony Lichaa1, Pauline KRUG1 and Adrien Nzeusseu Toukap2, 1Cliniques universitaires St-Luc, Brussel, Belgium, 2Cliniques universitaires Saint-Luc,, St.-Lambrechts-Woluwe, Belgium

    Background/Purpose: Axial spondyloarthritis (axSpA) is a progressive disease, characterized by chronic inflammation and progressive structural damage. However, the kinetic of progression to ankylosis and much…
  • Abstract Number: 0581 • ACR Convergence 2024

    Unmet Criteria for Achieving Minimal and Very Low Disease Activity Among Patients with Psoriatic Arthritis Initiating Biologic or Targeted Synthetic Disease-Modifying Antirheumatic Drugs in the CorEvitas PsA/SpA Registry

    Alexis Ogdie1, Chao Song2, Nicole Middaugh3, Maya Marchese3, Melissa Eliot3, Robert Low2 and Philip Mease4, 1Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 2UCB Pharma, Smyrna, GA, 3CorEvitas, LLC, Waltham, MA, 4Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA

    Background/Purpose: Minimal disease activity (MDA) is associated with reduced radiographic progression and improved quality of life among patients (pts) with PsA.1 Clinical advances made MDA…
  • Abstract Number: 0432 • ACR Convergence 2024

    Disease Activity During Pregnancy in Patients with Rheumatoid Arthritis or Spondyloarthritis: Results from the Multicentre Prospective GR2 Study

    Marion couderc1, celine lambert2, sabrina hamroun3, denis gallot4, Nathalie Costedoat-chalumeau5, Laure Gossec6, Gaëlle Guettrot-Imbert7, Veronique LE GUERN7, Christophe Richez8, MArtin Soubrier9 and Anna Molto10, 1CHU de Clermont-Ferrand, Clermont-Ferrand, 2chu clermont ferrand, clermont ferrand, France, 3Rheumatology Department - Cochin Hospital, Paris, France, 4Department of Obstetrics, CHU Clermont-ferrand, Clermont-Ferrand, Auvergne, France, 5University Paris Cité, Paris, France, 6Sorbonne Université, Paris, France, 7Cochin Hospital, Paris, France, 8Université de Bordeaux, Bordeaux, France, 9Gabriel-Montpied Hospital, Clermont-ferrand, France, 10Groupe Hospitalier Cochin, AP-HP, Paris, France

    Background/Purpose: Pregnancy may have a beneficial effect on disease activity in rheumatoid arthritis (RA) but the evidence is more conflicting in spondyloarthritis (SpA). The aim…
  • Abstract Number: 0683 • ACR Convergence 2024

    Prognostic Value of Systemic Sclerosis-associated Primary Heart Involvement

    Caya Gharibian1, Vanessa Lupi1, Alexander Gotschy1, Mike Becker2, Rucsandra Dobrota1, Muriel Elhai3, Sinziana Muraru1, Suzana Jordan1, Anna-Maria Hoffmann-Vold4, Oliver Distler5, Robert Manka1, Cosimo Bruni1 and Carina Mihai1, 1University Hospital Zurich, University of Zurich, Zurich, Switzerland, 2Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, 3University Hospital zurich, Zürich, Switzerland, 4Oslo University Hospital, Oslo, Norway, 5Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, Zurich, Switzerland

    Background/Purpose: A definition of primary heart involvement (pHI) in systemic sclerosis (SSc) was recently developed (Bruni C et al. J Scleroderma Relat Disord. 2022;7:24-32). Cardiac…
  • Abstract Number: 0663 • ACR Convergence 2024

    Treatment Patterns and the Prevalence of Kidney Biopsy-Confirmed LN in Patients with SLE and Proteinuria: A Multicenter Cohort Study

    Arushi Ramnarain1, Xiaomeng Xu2, Joanna Kent3, Sagar Jagtiani4, Worawit Louthrenoo5, Laniyati Hamijoyo6, Shue-Fen Luo7, Yi-Hsing Chen8, Jiacai Cho9, Chiu Wai Shirley Chan10, Sandra Navarra11, Haihong Yao12, Lydia Pok13, BMDB Basnayake14, Zhuoli Zhang15, Madelynn Chan16, Sang-Cheol Bae17, Yasuhiro Katsumata18, Jun Kikuchi19, Sean O'Neill20, Fiona Goldblatt21, Yih Jia Poh22, Mark Sapsford23, Nicola Tugnet24, Kristine Pek Ling Ng25, Cherica Tee26, Yoshiya Tanaka27, Mandana Nikpour28, Alberta Hoi29, Eric Morand30 and Rangi Kandane-Rathnayake31, 1Monash Health, Melbourne, Victoria, Australia, 2GSK, Value, Evidence & Outcomes, Singapore, Singapore, 3Monash University, Department of Nephrology, Monash Health and Department of Medicine, Melbourne, Australia, 4Glaxo Smith Kline, Singapore, Singapore, 5Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand, Chiang Mai, Thailand, 6Hasan Sadikin Hospital, Jakarta Selatan, Indonesia, 7Chang Gung Memorial Hospital, Taipei, Taiwan, 8Taichung Veterans General Hospital, Taichung, TW, Taichung, Taiwan (Republic of China), 9National University Hospital, Singapore, Singapore, 10Division of Rheumatology and Clinial Immunology, Department of Medicine, the University of Hong Kong, Hong Kong, Hong Kong, China, 11University of Santo Tomas, Manila, Philippines, 12People's Hospital, Peking University Health Science Center, Department of Rheumatology and Immunology, Beijing, China, 13University of Malaya Medical Center, Department of Medicine, Faculty of Medicine,, Kuala Lumpur, Malaysia, 14Teaching Hospital, Kandy, Sri Lanka, 15Peking University First Hospital, Beijing, China, 16Tan Tock Seng Hospital, Singapore, Singapore, 17Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, 18Tokyo Women's Medical University School of Medicine, Tokyo, Japan, 19Keio University School of Medicine, Tokyo, Japan, 20Liverpool Hospital; Royal North Shore Hospital; University of New South Wales and the University of Sydney, Sydney, New South Wales, Australia, 21Flinders Medical Centre, Adelaide, Australia, 22SingHealth, Singapore, Singapore, 23WDHB, Auckland, New Zealand, 24Auckland District Health Board, Auckland, New Zealand, 25Health New Zealand, Auckland, New Zealand, 26Department of Pediatrics, College of Medicine, University of the Philippines, Manila, Philippines, 27Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan, 28The University of Sydney, Melbourne, Victoria, Australia, 29Monash Health, Monash University, Melbourne, AU, Melbourne, Victoria, Australia, 30School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia, 31Monash University, Clayton, Victoria, Australia

    Background/Purpose: LN is a common and severe manifestation of SLE. Although proteinuria is a useful diagnostic indicator, kidney biopsy is necessary for definitive diagnosis and…
  • Abstract Number: 0679 • ACR Convergence 2024

    Comparing Raynaud’s Phenomenon Measurement Tools: Results of the Optimizing Raynaud Phenomenon Outcome Measures in Systemic Sclerosis (ROSS) Study

    Rachel Wallwork1, Haomin Hu2, Ami Shah3, Laura Hummers4, John Pauling5, Victoria Flower6, Bambang Parmanto2, Andi Saptono2 and Robyn Domsic7, 1Johns Hopkins University, Towson, MD, 2University of Pittsburgh, Pittsburgh, PA, 3Division of Rheumatology, Johns Hopkins University, Ellicott City, MD, 4Johns Hopkins University, Division of Rheumatology, Baltimore, MD, Ellicott City, MD, 5North Bristol NHS Trust, Bristol, United Kingdom, 6Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, 7Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA

    Background/Purpose: Raynaud’s phenomenon (RP) is the most common symptom in systemic sclerosis (SSc) and can lead to significant morbidity, including digital ulcers and/or gangrene.  Despite…
  • Abstract Number: 0619 • ACR Convergence 2024

    Prevalence and Factors Predicting Hemophagocytic Lymphohistiocytosis in Hospitalized Patients with Systemic Lupus Erythematosus

    OKEOGHENE AKPOIGBE1, BETTINA ESCOLANO2, ENOCH J ABBEY2 and Amanda Sammut3, 1New York City Health and Hospitals/Harlem in Affliation with Columbia University, NEW YORK, NY, 2New York City Health and Hospitals/Harlem in Affliation with Columbia University, NEW YORK, 3New York City Health and Hospitals/Harlem. Rheumatology Department, Chappaqua, NY

    Background/Purpose: Systemic lupus erythematosus (SLE) complicated with hemophagocytic lymphohistiocystosis (HLH) can be life-threatening with mortality as high as 9.9%-10.5%. Estimates of the prevalence of HLH…
  • « Previous Page
  • 1
  • …
  • 45
  • 46
  • 47
  • 48
  • 49
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology